ABSTRACT BACKGROUND Transvenous implantable cardioverter-defibrillators (TV-ICDs) improve survival in patients at risk for
leads are associated with both infective and mechanical complications, such as lead endocarditis, pneumothorax, venous occlusion, and cardiac perforation (4, 5) . Lead failure may cause inappropriate shocks and impede delivery of appropriate therapy for ventricular arrhythmias (6) (7) (8) .
The subcutaneous implantable cardioverterdefibrillator (S-ICD) was designed to eliminate complications related to transvenous leads, but lacks pacing capabilities and can therefore only be used in patients without a need for pacing (9) . Studies of the S-ICD have demonstrated clinical efficacy, but also reported a 13.1% inappropriate shock rate at 3 years follow-up, which was significantly reduced with dual-zone programming (10) (11) (12) . How- PROPENSITY SCORE MATCHING. Propensity score matching was performed with patients for whom complete baseline variables were available (total N ¼ 1,154). Analysis of excluded patients due to missing baseline data did not suggest selection bias.
We used logistic multivariable regression with device type (S-ICD or TV-ICD) as the dependent variable and 16 baseline variables as independent predictors to calculate the propensity score (Table 1, Online Table   1 ). The Harrell's C-statistic for the propensity score Genetic arrhythmia syndrome 79 (53) 240 (18) 75 (54) 54 (39) Nonischemic cardiomyopathy 30 (20) 179 (14) 28 (20) 30 (21) Congenital heart disease 5 (3) 49 (4) 5 (4) 12 (9) Family history of SCD 7 (5) 3 (0) 6 (4) Moderate (eGFR 30-60 ml/min) 11 (8) 214 (17) 10 (7) 8 (6) Poor (eGFR <30 ml/min) 2 (1) 31 (2) 2 (1) 
Values are median (interquartile range), n (%), or %. *Standardized mean difference is the difference in group means divided by the control standard deviation. Absolute values <0.2 suggest balance between propensity-matched groups.
eGFR ¼ estimated glomerular filtration rate; NYHA ¼ New York Heart Association; S-ICD ¼ subcutaneous implantable cardioverter-defibrillator; SCD ¼ sudden cardiac death; TV-ICD ¼ transvenous implantable cardioverter-defibrillator.
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Comparison of S-ICD and TV-ICD Therapy with less comorbidity, higher left ventricular ejection fractions (50%), and genetic arrhythmia syndromes as the main diagnosis (53%).
PROPENSITY-MATCHED COHORT. In the propensitymatched cohort, S-ICD cases (n ¼ 140) were similar to their TV-ICD controls (n ¼ 140), with no significant differences in any baseline characteristics ( Table 1 Brouwer et al. 14.6% to 59.7%) leads failed at 5 years. In the other abbreviations as in Figure 1 .
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